WELL Health Technologies Corp (WELL – Research Report), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. The Healthcare company, WELL Health Technologies Corp (TSX: WELL) has just received a rating update from a Wall Street analyst.
According to TipRanks.com, Keywood is a 4-star analyst with an average return of 1.3% and a 42.7% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Andlauer Healthcare Group, Cipher Pharmaceuticals, and Knight Therapeutics.
Currently, the analyst consensus on WELL Health Technologies Corp is a Strong Buy with an average price target of C$8.44, an 87.1% upside from current levels. In a report issued on July 19, TD Securities also reiterated a Buy rating on the stock with a C$8.50 price target.
WELL Health Technologies Corp’s market cap is currently C$1.07B and has a P/E ratio of -239.36.
WELL Health Technologies Corp is the owner and operator of a portfolio of Primary Hclinics delivering healthcare-related services It operates through below segments: Clinical services, Digital services, and others. It also engages in the Electronic Medical Records business that supports the digitization of clinics. Its objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.
The company’s shares closed last Thursday at C$4.46.
Read More on TSE:WELL:
